Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford team who have developed a COVID-19 vaccine in record time have been shortlisted for the Excellence in Healthcare Award at the NHS Parliamentary Awards.

Scientists analyzing covid 19 sample with microscope and holding covid 19 blood sample tube

The team from the Oxford Vaccine Group and Jenner Institute were nominated by Layla Moran, MP for Oxford West and Abingdon, and won the regional Excellence in Healthcare award.

The news coincided with announcement of interim data from phase III of the vaccine trial, which showed that the Oxford candidate vaccine was effective at preventing COVID-19 and offered a high level of protection. One dosing regimen indicated that the vaccine is 90 percent effective.

Layla Moran said:

"I'm absolutely delighted. There were nearly 700 nominations by MPs this year, so to be shortlisted is a huge achievement - the vaccine team really deserve it!

"The Oxford Vaccine Group and the Jenner Institute have been working so incredibly hard since the beginning of the pandemic to produce a vaccine that will be life changing for so many people around the world. They're the jewel in our community's crown"

The NHS Parliamentary Awards are an annual opportunity to recognise and appreciate the very best about our local healthcare service.

The full story is available on the Oxford University Hospitals website

Similar stories

Oxford vaccine researchers talk research and home-schooling on ITV's This Morning

COVID-19 Public Engagement

Professor Katie Ewer (The Jenner Institute) and Dr Maheshi Ramasamy (Oxford Vaccine Group) appeared on ITV's This Morning on Wednesday 6 January to talk about their work developing the ChAdOx1 nCoV-19 coronavirus vaccine, all while juggling the demands of young families and home-schooling.

Oxford vaccine stimulates broad antibody and T cell functions

COVID-19 Publication Research

Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

COVID-19

University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

Philharmonic Orchestra film special tribute concert for the Oxford vaccine team

Awards & Appointments COVID-19

A special concert to say thank you and pay tribute to the achievements of the Oxford vaccine team has been recorded at the Sheldonian Theatre for a film screening in time for Christmas

Oxford University breakthrough on global COVID-19 vaccine

COVID-19 Publication

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.